Cipla arm's oral liquid dosage, nasal product unit acquired by Rubicon Research
New Delhi: Specialty pharma firm Rubicon Research on Friday said it has acquired Meditab Specialities'' oral liquid dosage and nasal product manufacturing facility at Satara in Maharashtra.
Meditab Specialities is a wholly-owned subsidiary of Cipla.
Without disclosing the deal size, Rubicon Research said the Satara facility is cGMP compliant and MHRA (UK)-inspected production site.
The facility enables a strong and diverse pipeline of oral liquids for Rubicon Research, it said in a statement.
The company will seek additional regulatory approvals for the Satara site, including from the United States Food and Drug Administration (USFDA), it added.
Read also: MSD in talks with 5 Indian drugmakers for clinical trial of COVID drug Molnupiravir
"The acquisition of an outstanding oral liquid and nasal inhalers manufacturing facility advances our plan to offer a wider portfolio to our customers," Rubicon Research CEO Parag Sancheti said.
These capabilities combined with Rubicon''s research and development expertise strengthens the company''s ability to offer best-in-class drug products across dosage forms, he added
Read also: Cipla gets DCGI nod to import Moderna COVID vaccine
